Comorbidity in lung cancer patients and its association with hospital readmission and fatality in China

BMC Cancer

Ping He¹  Dawei Zhu¹  Ruoxi Ding¹  Yong Ma²  Zhishui Chen³  Xuefeng Shi⁴ 

[1] China Center for Health Development Studies, Peking University, 100191, Beijing, China;China Health Insurance Research Association, 100013, Beijing, China;Department of Medical Insurance, Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), 100142, Beijing, China;School of Management, Beijing University of Chinese Medicine, 100029, Beijing, China;

关键词: Lung cancer;    Comorbidity;    China;    Urban;   

DOI  :  10.1186/s12885-021-08272-y

来源: Springer

【 摘 要 】

BackgroundComorbidity has been established as one of the important predictors of poor prognosis in lung cancer. In this study, we analyzed the prevalence of main comorbidities and its association with hospital readmission and fatality for lung cancer patients in China.MethodsThe analyses are based on China Urban Employees’ Basic Medical insurance (UEBMI) and Urban Residents’ Basic Medical Insurance (URBMI) claims database and Hospital Information System (HIS) Database in the Beijing University Cancer Hospital in 2013–2016. We use Elixhauser Comorbidity Index to identify main types of comorbidities.ResultsAmong 10,175 lung cancer patients, 32.2% had at least one comorbid condition, and the proportion of patients with one, two, and three or more comorbidities was 21.7, 8.3 and 2.2%, respectively. The most prevalent comorbidities identified were other malignancy (7.5%), hypertension (5.4%), pulmonary disease (3.7%), diabetes mellitus (2.5%), cardiovascular disease (2.4%) and liver disease (2.3%). The predicted probability of having comorbidity and the predicted number of comorbidities was higher for middle elderly age groups, and then decreased among patients older than 85 years. Comorbidity was positively associated with increased risk of 31-days readmission and in-hospital death.ConclusionOur study is the first to provide an overview of comorbidity among lung cancer patients in China, underlines the necessity of incorporating comorbidity in the design of screening, treatment and management of lung cancer patients in China.

【 授权许可】

CC BY